Epigenetics in Cancer: A Hematological Perspective

Maximilian Stahl, Nathan Kohrman, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan, Thomas Prebet

Research output: Contribution to journalReview articlepeer-review

Abstract

For several decades, we have known that epigenetic regulation is disrupted in cancer. Recently, an increasing body of data suggests epigenetics might be an intersection of current cancer research trends: next generation sequencing, immunology, metabolomics, and cell aging. The new emphasis on epigenetics is also related to the increasing production of drugs capable of interfering with epigenetic mechanisms and able to trigger clinical responses in even advanced phase patients. In this review, we will use myeloid malignancies as proof of concept examples of how epigenetic mechanisms can trigger or promote oncogenesis. We will also show how epigenetic mechanisms are related to genetic aberrations, and how they affect other systems, like immune response. Finally, we will show how we can try to influence the fate of cancer cells with epigenetic therapy.

Original languageEnglish (US)
Article numbere1006193
JournalPLoS genetics
Volume12
Issue number10
DOIs
StatePublished - Oct 2016

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Molecular Biology
  • Genetics
  • Genetics(clinical)
  • Cancer Research

Fingerprint Dive into the research topics of 'Epigenetics in Cancer: A Hematological Perspective'. Together they form a unique fingerprint.

Cite this